000177019 001__ 177019
000177019 005__ 20240229133729.0
000177019 0247_ $$2doi$$a10.1007/s00432-021-03825-x
000177019 0247_ $$2pmid$$apmid:34642793
000177019 0247_ $$2ISSN$$a0084-5353
000177019 0247_ $$2ISSN$$a0171-5216
000177019 0247_ $$2ISSN$$a0943-9382
000177019 0247_ $$2ISSN$$a1432-1335
000177019 0247_ $$2altmetric$$aaltmetric:115145830
000177019 037__ $$aDKFZ-2021-02249
000177019 041__ $$aEnglish
000177019 082__ $$a610
000177019 1001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b0$$eFirst author$$udkfz
000177019 245__ $$aHealth and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study.
000177019 260__ $$aHeidelberg$$bSpringer$$c2022
000177019 3367_ $$2DRIVER$$aarticle
000177019 3367_ $$2DataCite$$aOutput Types/Journal article
000177019 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642492462_14352
000177019 3367_ $$2BibTeX$$aARTICLE
000177019 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177019 3367_ $$00$$2EndNote$$aJournal Article
000177019 500__ $$a#EA:C071#LA:C071# / 2022 Jan;148(1):155-162
000177019 520__ $$aLimited research suggests that cancer survivors have problems with insurance. Our study aimed to gain insight into the proportion of very long-term (14-24 years post-diagnosis) survivors of breast, colorectal, and prostate cancers who had problems with health (HI) and life (LI) insurance.We used data from CAESAR (CAncEr Survivorship-A multi-Regional population-based study). Participants completed questions on change in insurance providers since cancer diagnosis, problems with requesting (additional) HI or LI, and how potential problems were resolved. We conducted logistic regression to determine factors associated with change in statutory HI.Of the 2714 respondents, 174 (6%) reported having changed HI providers. Most switched between different statutory HI providers (86%), 9% from statutory to private, and 5% from private to statutory. Respondents who changed statutory HI providers were more likely to be prostate cancer survivors (OR 2.79, 95% CI 1.01-7.68) while being ≥ 65 years at time of diagnosis (OR 0.58, 95% CI 0.35-0.96) and having ≥ 2 comorbid conditions (OR 0.61, 95% CI 0.40-0.92) were associated with reduced odds for change. Problems in changing HI were minimal and were resolved with additional contribution. Of the 310 respondents who tried to get LI, 25 respondents reported having difficulties, of whom the majority had their request rejected.Most cancer survivors did not change their HI nor tried to buy LI after cancer diagnosis. Problems with changing statutory HI were generally resolved with additional contribution while the main problem encountered when buying LI was rejection of request.
000177019 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177019 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177019 650_7 $$2Other$$aCancer survivors
000177019 650_7 $$2Other$$aFinancial toxicity
000177019 650_7 $$2Other$$aInsurance problems
000177019 650_7 $$2Other$$aPopulation-based
000177019 7001_ $$0P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDoege, Daniela$$b1$$udkfz
000177019 7001_ $$00000-0003-4404-5131$$aWeißer, Linda$$b2
000177019 7001_ $$0P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aKoch-Gallenkamp, Lena$$b3$$udkfz
000177019 7001_ $$aBertram, Heike$$b4
000177019 7001_ $$00000-0003-4195-5236$$aEberle, Andrea$$b5
000177019 7001_ $$aHolleczek, Bernd$$b6
000177019 7001_ $$00000-0002-7115-5160$$aNennecke, Alice$$b7
000177019 7001_ $$00000-0002-5909-9936$$aWaldmann, Annika$$b8
000177019 7001_ $$00000-0002-0743-6128$$aZeissig, Sylke Ruth$$b9
000177019 7001_ $$00000-0002-2858-2941$$aPritzkuleit, Ron$$b10
000177019 7001_ $$0P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aSchlander, Michael$$b11$$udkfz
000177019 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b12$$udkfz
000177019 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b13$$eLast author$$udkfz
000177019 773__ $$0PERI:(DE-600)1459285-X$$a10.1007/s00432-021-03825-x$$n1$$p155-162$$tJournal of cancer research and clinical oncology$$v148$$x0171-5216$$y2022
000177019 909CO $$ooai:inrepo02.dkfz.de:177019$$pVDB
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55389e9f54d8411e6e6eddcec489bb1b$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$60000-0003-4404-5131$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13aa5fe9d9961c9fd67193befb0dcf88$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1f315d09721b91091df1ba78eb65cbaf$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000177019 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000177019 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177019 9141_ $$y2021
000177019 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-31$$wger
000177019 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-31
000177019 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-31
000177019 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-31
000177019 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CANCER RES CLIN : 2021$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-17
000177019 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-17
000177019 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000177019 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x1
000177019 9201_ $$0I:(DE-He78)C100-20160331$$kC100$$lGesundheitsökonomie$$x2
000177019 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x3
000177019 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x4
000177019 980__ $$ajournal
000177019 980__ $$aVDB
000177019 980__ $$aI:(DE-He78)C071-20160331
000177019 980__ $$aI:(DE-He78)C070-20160331
000177019 980__ $$aI:(DE-He78)C100-20160331
000177019 980__ $$aI:(DE-He78)C120-20160331
000177019 980__ $$aI:(DE-He78)HD01-20160331
000177019 980__ $$aUNRESTRICTED